PEN 110

Drug Profile

PEN 110

Alternative Names: INACTINE; INACTINE™ Pathogen Inactivation red blood cell product; INACTINE™ Pathogen Reduction System for Red Cells; PEN110

Latest Information Update: 05 Jul 2005

Price : $50

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Polyamines
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Graft-versus-host disease; Infections

Most Recent Events

  • 05 Jul 2005 Discontinued - Preclinical for Graft-versus-host disease in USA (Extracorporeal)
  • 05 Jul 2005 Discontinued - Phase-III for Infections in USA (Extracorporeal)
  • 05 Jul 2005 The INACTINE system is available for licensing (http://www.vitechnologies.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top